Nichols & Pratt Advisers LLP MA boosted its stake in shares of Medtronic PLC (NYSE:MDT) by 0.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 95,666 shares of the medical technology company’s stock after buying an additional 225 shares during the period. Nichols & Pratt Advisers LLP MA’s holdings in Medtronic PLC were worth $8,265,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Beach Investment Counsel Inc. PA raised its stake in Medtronic PLC by 2.0% in the second quarter. Beach Investment Counsel Inc. PA now owns 282,436 shares of the medical technology company’s stock valued at $24,507,000 after buying an additional 5,510 shares in the last quarter. Huntington National Bank raised its stake in Medtronic PLC by 10.9% in the second quarter. Huntington National Bank now owns 227,847 shares of the medical technology company’s stock valued at $19,769,000 after buying an additional 22,309 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in Medtronic PLC by 5.1% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 123,450 shares of the medical technology company’s stock valued at $10,713,000 after buying an additional 5,980 shares in the last quarter. Clarkston Capital Partners LLC raised its stake in Medtronic PLC by 3.3% in the second quarter. Clarkston Capital Partners LLC now owns 120,828 shares of the medical technology company’s stock valued at $10,484,000 after buying an additional 3,840 shares in the last quarter. Finally, Montag & Caldwell LLC raised its stake in Medtronic PLC by 16.3% in the second quarter. Montag & Caldwell LLC now owns 2,318,700 shares of the medical technology company’s stock valued at $201,194,000 after buying an additional 324,802 shares in the last quarter. Institutional investors own 80.95% of the company’s stock.

Institutional Ownership by Quarter for Medtronic PLC (NYSE:MDT)

Shares of Medtronic PLC (NYSE:MDT) traded down 1.042% during trading on Wednesday, reaching $72.655. The company had a trading volume of 6,685,798 shares. The company has a market capitalization of $100.26 billion, a PE ratio of 24.194 and a beta of 1.01. The stock’s 50-day moving average price is $81.50 and its 200-day moving average price is $84.68. Medtronic PLC has a 52 week low of $71.03 and a 52 week high of $89.27.

Medtronic PLC (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 22nd. The medical technology company reported $1.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.01. The business earned $7.35 billion during the quarter, compared to analyst estimates of $7.46 billion. Medtronic PLC had a return on equity of 12.36% and a net margin of 14.63%. The company’s revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the business posted $1.03 EPS. On average, equities analysts expect that Medtronic PLC will post $4.63 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2016/11/30/nichols-pratt-advisers-llp-ma-boosts-position-in-medtronic-plc-mdt.html.

MDT has been the topic of several analyst reports. Vetr raised Medtronic PLC from a “buy” rating to a “strong-buy” rating and set a $90.83 target price on the stock in a report on Tuesday, November 1st. Deutsche Bank AG reissued a “buy” rating on shares of Medtronic PLC in a report on Monday, October 31st. Evercore ISI reissued a “buy” rating and issued a $80.00 target price (down from $94.00) on shares of Medtronic PLC in a report on Monday. Zacks Investment Research raised Medtronic PLC from a “hold” rating to a “buy” rating and set a $92.00 target price on the stock in a report on Wednesday, October 26th. Finally, Oppenheimer Holdings Inc. set a $94.00 target price on Medtronic PLC and gave the stock a “buy” rating in a report on Tuesday, November 22nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty have issued a buy rating to the stock. Medtronic PLC presently has an average rating of “Buy” and an average target price of $88.19.

In related news, VP Richard Kuntz sold 25,199 shares of Medtronic PLC stock in a transaction dated Monday, September 26th. The stock was sold at an average price of $86.67, for a total value of $2,183,997.33. Following the completion of the transaction, the vice president now owns 149,425 shares in the company, valued at approximately $12,950,664.75. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Omar Ishrak sold 61,925 shares of Medtronic PLC stock in a transaction dated Thursday, September 15th. The shares were sold at an average price of $84.93, for a total value of $5,259,290.25. Following the completion of the transaction, the chief executive officer now owns 565,916 shares of the company’s stock, valued at approximately $48,063,245.88. The disclosure for this sale can be found here. Company insiders own 0.25% of the company’s stock.

About Medtronic PLC

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

5 Day Chart for NYSE:MDT

Receive News & Stock Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related stocks with our FREE daily email newsletter.